A widely used combination of anti-aging drugs is causing significant damage to the brains of mice, according to research published this week by the University of Connecticut. The two-drug cocktail, dasatinib and quercetin (D+Q), induces myelin loss in the corpus callosum – a critical brain structure – and appears to impair the function of cells responsible for rebuilding myelin, raising concerns about its potential impact on human neurological health.
The findings, detailed in the March 16 issue of PNAS, show that administering D+Q to mice, both young and old, results in the deterioration of myelin, the protective insulation around nerve fibers. “When you administer this cocktail to an animal, young or old, the myelin is damaged, which makes it disappear,” explained UConn School of Medicine immunologist Stephen Crocker. “Even worse in the young animals” than in the aged ones, Crocker added.
Myelin loss is a hallmark of multiple sclerosis (MS), a debilitating autoimmune disease affecting the central nervous system. Crocker and his team observed that D+Q treatment led to the dysfunction of oligodendrocytes, the cells responsible for producing and maintaining myelin. These affected cells reverted to an immature state, mirroring those found in MS lesions, areas of damaged tissue in the nervous system.
D+Q has gained popularity in anti-aging research due to its ability to eliminate senescent cells – aged cells that contribute to inflammation and age-related symptoms. We see currently being investigated as a potential treatment for conditions ranging from type II diabetes to Alzheimer’s disease. However, the UConn study highlights a previously overlooked potential side effect. While some individuals are already using the drug combination “off-label” in pursuit of anti-aging benefits, the medical community generally discourages this practice.
The research revealed a particularly concerning trend: younger mice experienced more severe myelin damage than older mice. This challenges the assumption that senolytic drugs – those targeting senescent cells – primarily benefit aged tissues. The observed damage in the corpus callosum, the major pathway connecting the two hemispheres of the brain, was significant enough to resemble the brain changes seen after chemotherapy, according to researchers.
The study’s findings have prompted calls for caution regarding the prophylactic utilize of D+Q. Medicalxpress.com reported that the research should make doctors cautious about prescribing the drug combination. The implications extend beyond anti-aging applications, as the observed oligodendrocyte dysfunction and demyelination could have broader neurological consequences.
Multiple Sclerosis News Today reported on March 20, 2026, that the lab study showed a “profound loss” of the protective myelin coating, a key characteristic of MS. Researchers are now investigating the mechanisms underlying this myelin damage, hoping to gain insights into both the adverse effects of D+Q and the progression of MS itself.
The University of Connecticut research team has not yet announced plans for human trials to assess the effects of D+Q on the human brain. Further investigation is needed to determine whether the findings in mice translate to humans and to understand the long-term consequences of D+Q exposure.
Leave a Reply